GlassScriptPhysician profile
Yelena Kisel
NPI 1619201654
$25,340.57
in general payments reported to CMS, 2019-2025
30 companies · $4,941 in 2025
The $4,941 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,757 · 2022: $4,465 · 2023: $5,926 · 2024: $6,252 · 2025: $4,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,428.18 |
| Education | $690.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,278.50 | 2021-2025 | |
| Janssen Biotech, INC. | $3,220.77 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $2,443.88 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $2,098.88 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,812.54 | 2021-2025 | |
| Amgen INC. | $1,238.00 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,217.76 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $1,067.05 | 2022-2025 | Sotyktu |
| Incyte Corporation | $1,033.79 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $905.76 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $877.41 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $855.36 | 2021-2025 | |
| Dermavant Sciences, INC. | $824.68 | 2022-2024 | Vtama |
| Pfizer INC. | $781.37 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $698.30 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $550.94 | 2021-2025 | Anzupgo, Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $326.44 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Sanofi-Aventis U.S. LLC | $229.97 | 2021-2025 | |
| Mission Pharmacal Company | $154.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.26 | 2022-2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $114.25 | 2022 | |
| Vyne Pharmaceuticals INC. | $113.64 | 2021 | |
| Organon LLC | $85.87 | 2024-2025 | Hadlima, Vtama |
| Sandoz INC. | $84.42 | 2023-2025 | Hyrimoz |
| Biofrontera INC. | $56.04 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $47.74 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $29.61 | 2023-2024 | Idacio |
| Allergan, INC. | $24.55 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $20.23 | 2025 | Valchlor |
| Dermira, INC. | $18.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Kisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.